Abstract
Diabetes management guidelines recommend escalating treatment when a certain HbA1c threshold is reached. Thus, predicting in an accurate way the natural progression of HbAc1 and as such treatment duration is of key importance in diabetes models (shorter or longer use of expensive therapies). Recently, the UK Prospective Diabetes Study (UKPDS) investigators published progression equations for several risk factors including HbA1c (UKPDS90). The aim of this study was to assess the duration to treatment escalation applying the different HbA1c progression equations included in the IQVIA Core Diabetes Model v9.5Plus (CDM9.5Plus).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
